Market Performance Overview
Elicio Therapeutics (ticker 9HA.F) experienced a decline of 12.36 % in the 24‑hour period ending at 02:18 PM Central Europe on Thursday, 22 October 2026. The stock is presently trading at approximately USD 1.67 on major exchanges.
- Shares outstanding: 26.3 million
- Market capitalisation: USD 41.3 million
- Volume traded in last 24 hours: USD 520.9 k
- Month‑end change: down 16.58 % since the previous month
- 200‑day simple moving average: USD 7.1
- 52‑week high: USD 16.00 (10 June 2026)
- 52‑week low: USD 1.55 (16 October 2026)
Related Stock Movements (Last 24 Hours)
| Company | Ticker | Change | Current Price | Market Capitalisation |
|---|---|---|---|---|
| Spectral Ai | MDAI | 0 % | USD 1.51 | USD 48.6 million |
| Fluence | 4SVE.F | 0 % | EUR 0.04 | EUR 43.5 million |
| Kalaris Therapeutics | KLRS | -2.42 % | USD 2.02 | USD 49.3 million |
| Adicet Bio | ACET | -0.66 % | USD 4.49 | USD 48.7 million |
| Tela Bio | TELA | -0.92 % | USD 1.08 | USD 49.2 million |
Company Profile
Elicio Therapeutics, Inc. is a biopharmaceutical firm headquartered in Boston, Massachusetts, United States. The company develops lymph‑node‑targeted immunotherapies and vaccines aimed at re‑engineering the immune response to combat cancer and infectious diseases. Elicio Therapeutics is listed on the Nasdaq stock exchange and provides further information on its website at www.elicio.com .